PHILADELPHIA–(BUSINESS WIRE)– #AZUR–Jemperli (dostarlimab-gxly) approved in US as first and only immunotherapy for adults with MSI-H/dMMR locally advanced rectal cancer
PHILADELPHIA–(BUSINESS WIRE)– #AZUR–Jemperli (dostarlimab-gxly) approved in US as first and only immunotherapy for adults with MSI-H/dMMR locally advanced rectal cancer